CAL
GLMD icon

Capital Analysts LLC’s Galmed Pharmaceuticals GLMD Stock Holding History

Capital Analysts LLC’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5
Closed -$3K – 997
2021
Q1 		$3K Buy
+5
New +$3.46K ﹤0.01% 915

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Capital Analysts LLC's GLMD Position: Q2 2021 in Review

Capital Analysts LLC sold out of Galmed Pharmaceuticals (GLMD) in Q2 2021, closing a stake of 5 shares — an estimated $3K sold.

Capital Analysts LLC first reported a position in GLMD in Q1 2021 and held it in 1 quarter. The position peaked at $3K in Q1 2021. 25 funds tracked by Wall St. Rank hold GLMD as of Q2 2021.

  • Capital Analysts LLC reported no remaining Galmed Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Capital Analysts LLC sold 5 Galmed Pharmaceuticals shares in Q2 2021, an estimated $3K.
  • Capital Analysts LLC first reported a position in Galmed Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Capital Analysts LLC's Galmed Pharmaceuticals position peaked at $3K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2021.

Based on Capital Analysts LLC's 13F filing for Q2 2021, filed 5 Aug 2021.